TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05839574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX monotherapy
Description: MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH), and subsequent hysteroscopic evacuation of products of conception (POC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX + letrozole add-on
Description: MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH) + Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0, and subsequent hysteroscopic evacuation of products of conception (POC)
Study: NCT04725253

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Nicotinamide, 1,5 gr per day for 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tablets, 1 per day for 7 days.
Study: NCT05753839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy±metastasectomy
Description: Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy±metastasectomy
Description: Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human-derived materials sampling
Description: Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, after induction therapy, and after 3 months of maintenance therapy.
Study: NCT06436534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir Oral Capsule
Description: 2-week treatment phase：Ganciclovir capsules(250mg), take 2 capsules twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ganciclovir Simulant Oral Capsule
Description: 2-week treatment phase：Ganciclovir simulant capsules(0mg), take 2 capsules twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Nasal
Description: From screening phase to follow-up phase：Mometasone furoate aqueous nasal spray(50μg/spray), take 1 spray once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone Nasal
Description: From screening phase to follow-up phase：Mometasone furoate aqueous nasal spray(50μg/spray), take 1 spray once a day
Study: NCT04648319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558
Description: BMS-936558 followed by 30 grays of 3 to 5 fractions of high dose SBRT followed by monthly BMS-936558 until progression
Study: NCT05057481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil 500mg
Description: MMF 2gram/day orally for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 of rituximab given intravenously weekly for 4 weeks.
Study: NCT06423456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.
Study: NCT05839171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music and mandala coloring
Description: Listening to music and coloring mandalas for women who have undergone embryo transfer and are waiting at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music and mandala coloring
Description: Listening to music and coloring mandalas for women who have undergone embryo transfer and are waiting at home
Study: NCT06028997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral and Sleep Hygiene Education with Mindfulness Intervention
Description: Education about good sleep hygiene practices and behavior advice to improve sleep based on current literature for 10-15 minutes/week followed by 50 minutes of yoga Nidra and breathing excersices
Study: NCT06368258

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red yeast rice
Description: Red yeast rice 160 mg (total monacolins 2.8 mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05334251

Intervention type: OTHER
Intervention: combined spinal-epidural anesthesia
Description: Combined spinal and epidural anaesthesia is a regional anaesthetic technique, which combines the benefits of both spinal anaesthesia and epidural anaesthesia and analgesia. The spinal component gives a rapid onset of a predictable block. The indwelling epidural catheter gives the ability to provide long lasting analgesia and to titrate the dose given to the desired effect.
Study: NCT05293067

Intervention type: DIAGNOSTIC_TEST
Intervention: high-sensitive troponin
Description: Values of high-sensitive troponin would be measured as follows: 1) preoperatively - one day before the planned intervention and 2) postoperatively - 8 hours after the operation and the first day after the operation.

Intervention type: DIAGNOSTIC_TEST
Intervention: high-sensitive troponin
Description: Values of high-sensitive troponin would be measured as follows: 1) preoperatively - one day before the planned intervention and 2) postoperatively - 8 hours after the operation and the first day after the operation.
Study: NCT04818619

Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometry test
Description: Blood samples will be stained with TIGIT by flow cytometry test

Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometry test
Description: Blood samples will be stained with TIGIT by flow cytometry test
Study: NCT04906746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.
Description: There will be intra-patient dose escalation of ruxolitinib in every patient enrolled on study.
Study: NCT01876355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SodiumChloride
Description: Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
Study: NCT04494074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Cooling
Description: External Cooling
Study: NCT04099966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha beta depletion
Description: donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.
Study: NCT06032832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soy protein concentrate-meat analog
Description: Baked Meat analogs-soy protein concentrate containing 57Fe as ferrous sulfate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soy protein concentrate-meat analog_dephytinization
Description: Baked dephytinized_Meat analogs-soy protein concentrate containing 58Fe as ferrous sulfate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Farinata
Description: Pancake made from chickpea flour contains 57Fe as ferrous sulfate
Study: NCT05986370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar spinal manipulative therapy
Description: Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham spinal manipulative therapy
Description: Sham spinal manipulative therapy (sham SMT), was designed to be structurally equivalent to SMT, i.e., to attend to the same body regions with the same amount of contact as well as to have the same number, frequency and length of sessions. SMT and sham SMT will be provided by the same treatment provider and will appear to be similarly tailored to the participants' condition. Sham SMT does not share the component of interest of SMT, i.e., the activation of deep high-threshold mechanoreceptors via high-velocity, low-amplitude thrusts applied to the spine. Yet, it shares all the other components not of interest in this study that may contribute to the placebo response, such as therapeutic alliance, contextual factors, physical touch, and expectations. Furthermore, deception will be used to balance expectations and enhance blinding.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full spine spinal manipulative therapy
Description: Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
Study: NCT06032832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Farinata_dephytinization
Description: Pancake made from dephytinized chickpea flour contains 58Fe as ferrous sulfate.
Study: NCT06069817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: home treatment with HFNC after airway stent placement both for malignant and benignant central airway obstruction
Study: NCT05247086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy
Description: After surgical wound closure we will apply negative pressure therapy
Study: NCT06725082

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Humanized Type III Collagen Injection
Description: rhCOL3/saline will be injected around the tumor (at four points: outer upper, inner upper, outer lower, and inner lower) before surgery, with 500ul per site. After the surgical margin is confirmed to be safe by rapid frozen pathology during surgery, a second injection of 2ml will be administered around the surgical area skin (at points spaced along the skin incision), followed by routine tissue flap revision and suture.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Type III Collagen Injection
Description: rhCOL3/saline will be injected around the tumor (at four points: outer upper, inner upper, outer lower, and inner lower) before surgery, with 500ul per site. After the surgical margin is confirmed to be safe by rapid frozen pathology during surgery, a second injection of 2ml will be administered around the surgical area skin (at points spaced along the skin incision), followed by routine tissue flap revision and suture.
Study: NCT06069817

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nebulized normal saline
Description: home treatment with nebulized normal saline after airway stent placement both for malignant and benignant central airway obstruction
Study: NCT05090735

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPIP and TAP Block
Description: Injection of Bupivacaine 0.25% for SPIP Block and TAP Block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPIP Block
Description: Injection of Bupivacaine 0.25% for SPIP Block
Study: NCT05182788

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pressed candy
Description: consume 2 tablets per day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CHOLESWISE pressed candy
Description: consume 2 tablets per day for 8 weeks
Study: NCT06062979

Intervention type: DRUG
Intervention: rilpivirine/cabotegravir
Description: WWH is currently providing Cabenuva treatment as a treatment option for eligible patients. The purpose of the proposed study is to use an observational, prospective cohort design to further investigate the delivery of Cabenuva among two subpopulations of WWH patients.

Intervention type: DRUG
Intervention: rilpivirine/cabotegravir
Description: WWH is currently providing Cabenuva treatment as a treatment option for eligible patients. The purpose of the proposed study is to use an observational, prospective cohort design to further investigate the delivery of Cabenuva among two subpopulations of WWH patients.
Study: NCT05405439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3823 tablets
Description: TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablets
Description: Abiraterone acetate tablet is an inhibitor of cytochrome P450 17（CYP17）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone acetate tablets
Description: Prednisone acetate tablet is a kind of glucocorticoids
Study: NCT06179576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect to Baby
Description: To engage both fathers and mothers, CTB recruits parents at the time of birth, capitalizing on the magic moment of delivery, and uses father-inclusive digital media content to engage men. A key innovation lies in the introduction and rehearsal of four interaction skills -- Noticing, Following, Talking, and Encouraging (NiFTE, pronounced Nifty) -- to foster serve-and-return interactions with infants as well as supportive, cooperative coparenting interactions between mothers and fathers. To maximize program uptake, CTB is situated within an early education program parents already trust and attend. Additionally, the study will test hybrid program delivery with both in-person and remote sessions using video-enabled tablets to reduce scheduling and logistical barriers and thereby enhance retention.
Study: NCT06261177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Description: 45 mins per day for the duration of 4 weeks (20 sessions).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham FES
Description: Sham FES
Study: NCT05020327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Graded Oral Amoxicillin Challenge
Description: Oral amoxicillin at 45 mg/kg (maximum of 1000 mg) to be divided into two doses: 10 % initial dose and then 90% remaining dose - doses will be separated by 30 minute interval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-labelling in electronic medical record
Description: Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.

Intervention type: OTHER
Group type: OTHER
Intervention: De-labelling in electronic medical record
Description: Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.
Study: NCT04608604

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Patients will be randomized in either physiotherapy 1 or physiotherapy 2. Physiotherapy programs are individually tailored based on a structured standardized series. In order to not unblind potential participants, detailed description of both interventions will be provided after recruitment has been finished.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Patients will be randomized in either physiotherapy 1 or physiotherapy 2. Physiotherapy programs are individually tailored based on a structured standardized series. In order to not unblind potential participants, detailed description of both interventions will be provided after recruitment has been finished.
Study: NCT06233188

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthogantic surgery
Description: surgery that correcting the maxilla and mandible related with each other

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthogantic surgery
Description: surgery that correcting the maxilla and mandible related with each other
Study: NCT05020327

Intervention type: OTHER
Group type: OTHER
Intervention: Referral to Allergy Immunology/Retention of Allergy Label
Description: Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to Allergy Immunology/Retention of Allergy Label
Description: Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.
Study: NCT04984434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F182112
Description: Eight dose cohorts: 0.01, 0.1, 0.3, 1, 3, 10, 20 and 30 μg/kg) d1 treat every weeks.
Study: NCT05062005

Intervention type: DRUG
Group type: OTHER
Intervention: Induction Chemotherapy
Description: Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.

Intervention type: DRUG
Group type: OTHER
Intervention: Concurrent Chemotherapy
Description: Cisplatin 100 mg/m², Q3w.

Intervention type: DRUG
Group type: OTHER
Intervention: Concurrent Chemotherapy
Description: Cisplatin 100 mg/m², Q3w.

Intervention type: RADIATION
Group type: OTHER
Intervention: Definitive Radiotherapy
Description: For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).

Intervention type: RADIATION
Group type: OTHER
Intervention: Definitive Radiotherapy
Description: For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
Study: NCT04930523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elongation Longitudinaux Avec Decoaption Osteo Articulaire
Description: Pre physiotherapy treatment~Gym (treadmill ,cycling,vibrator) according to ability and condition of patient Shortwave diathermy SWD for atleast 10 mins Decompression treatment i.e. Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes.~Post physiotherapy treatment~Conventional Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension,by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~No exercises or walk were guided for home (till 24 hrs) Low back exs guided i.e knee to chest, pelvic rolling, bridging, SLR, pirformis exs is guided for home plan along with precautions.~No exertion ,drive carefully Avoid stairs climbing ,twisting ,bending ,weight lifting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Pre physiotherapy treatment~Gym (treadmill ,cycling, vibrator) according to ability and condition of patient Shortwave diathermy SWD for at least 10 minutes. ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precautions.~Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes. Post physiotherapy treatment Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension, by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~ELDOA exercises(positions)are guided for home plan after session (after 24 hrs) No exertion ,drive carefully Avoid stairs climbing, twisting bending, weight lifting
Study: NCT06172686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).
Description: The first arm will receive Piperaquine tablets, that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.
Description: The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.
Study: NCT05938621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral therapy and education
Description: Sessions that focus on developing self-awareness and strategies to improve well-being will be the focus of the interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral therapy and education
Description: Sessions that focus on developing self-awareness and strategies to improve well-being will be the focus of the interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral therapy and education
Description: Sessions that focus on developing self-awareness and strategies to improve well-being will be the focus of the interventions.
Study: NCT06346834

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sIPV
Description: One dose of the experimental/control vaccine will be administered to 4-month-old infants who have already received two doses of sIPV from Beijing Institute of Biological Products Co., LTD.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: One dose of the experimental/control vaccine will be administered to 4-month-old infants who have already received two doses of sIPV from Beijing Institute of Biological Products Co., LTD.
Study: NCT04581486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal-Massive Intervention
Description: Multimodal intervention based on 3 main measures: a) optimal fluid viscosity adaptation (with Nutilis Clear®), b) optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and c) optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning).

Intervention type: OTHER
Group type: OTHER
Intervention: Control (standard clinical practice)
Description: Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))